Who is the manufacturer of Selpercatinib?

Selpercatinib/Selpercatinib is a targeted therapy drug mainly used to treat non-small cell lung cancer and other related cancers carrying RET gene mutations. Its manufacturer is Eli Lilly and Company, a global pharmaceutical company headquartered in the United States. Founded in 1876, Eli Lilly is committed to the development and production of innovative drugs covering multiple therapeutic areas, including oncology, diabetes, immunology, etc.

In the research and development of anti-tumor drugs in recent years, Eli Lilly has promoted the concept of precision medicine, focused on tumor genome research, and is committed to discovering and developing treatment options that can effectively target specific gene mutations. The development of Seputinib is a successful manifestation of this strategy. The drug has shown good results in clinical trials and can effectively inhibit the growth of tumor cells and significantly improve the survival prognosis of patients.

Seputinib was approved by the U.S. Food and Drug Administration (FDA) in 2020. It has received widespread attention as a targeted therapy for the treatment of RET gene rearrangement-positive non-small cell lung cancer and other types of tumors. Its launch also marks the further application of precision medicine in cancer treatment, providing new treatment options for many patients.

In terms of production, Eli Lilly adheres to strict quality management standards to ensure that each batch of Seputinib complies with international pharmaceutical production standards. This involves not only the selection and testing of raw materials, but also the monitoring of the entire production process and the quality inspection of the final product. In addition, Lilly also actively participates in follow-up studies of drugs to evaluate their long-term efficacy and safety, and continuously optimizes drug regimens.

Reference materials:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-medullary-thyroid-cancer-ret-mutation